Animal Welfare in Pharmaceutical Testing

Pharmaceutical development relies heavily on animal testing — regulatory requirements, 3Rs implementation, and alternatives development are all shaping the welfare landscape.

Key Facts

All pharmaceuticals must be tested in animals before human clinical trials in most jurisdictions
The FDA Modernization Act 2.0 (2022) removed the requirement for animal testing in drug approval
In vitro, organoid, and computer models are increasingly replacing some animal tests
Non-human primates are used for testing biological drugs including vaccines and monoclonal antibodies
Refinement of dosing methods, housing, and endpoints has reduced suffering in pharmaceutical animal studies

Welfare Considerations

Pharmaceutical testing animal welfare sits at the intersection of regulatory requirement, scientific validity, and alternatives development. The 2022 FDA Modernization Act in the US was a landmark shift, removing mandatory animal testing for drug approval and opening pathways for alternatives. However, many pharmaceutical companies and regulators retain animal testing requirements for biological safety assessment. The welfare burden remains enormous — hundreds of millions of animals annually. Refinement of existing testing methods alongside replacement investment produces the best near-term welfare outcomes while the science of alternatives matures. International regulatory harmonization on alternatives acceptance is critical to accelerating this transition.

What You Can Do

Support organizations advocating for pharmaceutical testing alternatives
Choose consumer products from companies with strong non-animal testing commitments
Engage with FDA and international regulatory consultations on alternatives acceptance
Support research into organ-on-chip, organoid, and computational alternatives to animal drug testing
Advocate for international regulatory harmonization that accelerates alternatives adoption